Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives
Bladder cancer is one of the most significant genitourinary cancer, causing high morbidity and mortality in a great number of patients. Over the years, various treatment methods for this type of cancer have been developed. The most common is the highly efficient method using Bacillus Calmette-Guerin...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/5/1181 |
| _version_ | 1797568650422517760 |
|---|---|
| author | Mikołaj Wołącewicz Rafał Hrynkiewicz Ewelina Grywalska Tomasz Suchojad Tomasz Leksowski Jacek Roliński Paulina Niedźwiedzka-Rystwej |
| author_facet | Mikołaj Wołącewicz Rafał Hrynkiewicz Ewelina Grywalska Tomasz Suchojad Tomasz Leksowski Jacek Roliński Paulina Niedźwiedzka-Rystwej |
| author_sort | Mikołaj Wołącewicz |
| collection | DOAJ |
| description | Bladder cancer is one of the most significant genitourinary cancer, causing high morbidity and mortality in a great number of patients. Over the years, various treatment methods for this type of cancer have been developed. The most common is the highly efficient method using Bacillus Calmette-Guerin, giving a successful effect in a high percentage of patients. However, due to the genetic instability of bladder cancer, together with individual needs of patients, the search for different therapy methods is ongoing. Immune checkpoints are cell surface molecules influencing the immune response and decreasing the strength of the immune response. Among those checkpoints, the PD-1 (programmed cell death protein-1)/PD-L1 (programmed cell death protein ligand 1) inhibitors aim at blocking those molecules, which results in T cell activation, and in bladder cancer the use of Atezolizumab, Avelumab, Durvalumab, Nivolumab, and Pembrolizumab has been described. The inhibition of another pivotal immune checkpoint, CTLA-4 (cytotoxic T cell antigen), may result in the mobilization of the immune system against bladder cancer and, among anti-CTLA-4 antibodies, the use of Ipilimumab and Tremelimumab has been discussed. Moreover, several different approaches to successful bladder cancer treatment exists, such as the use of ganciclovir and mTOR (mammalian target of rapamycin) kinase inhibitors, IL-12 (interleukin-12) and COX-2 (cyclooxygenase-2). The use of gene therapies and the disruption of different signaling pathways are currently being investigated. Research suggests that the combination of several methods increases treatment efficiency and the positive outcome in individual. |
| first_indexed | 2024-03-10T19:59:01Z |
| format | Article |
| id | doaj.art-07a690b2afb24ab5b65f9854ef0993a3 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:59:01Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-07a690b2afb24ab5b65f9854ef0993a32023-11-19T23:41:01ZengMDPI AGCancers2072-66942020-05-01125118110.3390/cancers12051181Immunotherapy in Bladder Cancer: Current Methods and Future PerspectivesMikołaj Wołącewicz0Rafał Hrynkiewicz1Ewelina Grywalska2Tomasz Suchojad3Tomasz Leksowski4Jacek Roliński5Paulina Niedźwiedzka-Rystwej6Institute of Biology, University of Szczecin, 71-412 Szczecin, PolandInstitute of Biology, University of Szczecin, 71-412 Szczecin, PolandDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, PolandDepartment of Urology, Regional Specialist Hospital, 26-060 Czerwona Góra, PolandDepartment of Urology, Regional Specialist Hospital, 26-060 Czerwona Góra, PolandDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, PolandInstitute of Biology, University of Szczecin, 71-412 Szczecin, PolandBladder cancer is one of the most significant genitourinary cancer, causing high morbidity and mortality in a great number of patients. Over the years, various treatment methods for this type of cancer have been developed. The most common is the highly efficient method using Bacillus Calmette-Guerin, giving a successful effect in a high percentage of patients. However, due to the genetic instability of bladder cancer, together with individual needs of patients, the search for different therapy methods is ongoing. Immune checkpoints are cell surface molecules influencing the immune response and decreasing the strength of the immune response. Among those checkpoints, the PD-1 (programmed cell death protein-1)/PD-L1 (programmed cell death protein ligand 1) inhibitors aim at blocking those molecules, which results in T cell activation, and in bladder cancer the use of Atezolizumab, Avelumab, Durvalumab, Nivolumab, and Pembrolizumab has been described. The inhibition of another pivotal immune checkpoint, CTLA-4 (cytotoxic T cell antigen), may result in the mobilization of the immune system against bladder cancer and, among anti-CTLA-4 antibodies, the use of Ipilimumab and Tremelimumab has been discussed. Moreover, several different approaches to successful bladder cancer treatment exists, such as the use of ganciclovir and mTOR (mammalian target of rapamycin) kinase inhibitors, IL-12 (interleukin-12) and COX-2 (cyclooxygenase-2). The use of gene therapies and the disruption of different signaling pathways are currently being investigated. Research suggests that the combination of several methods increases treatment efficiency and the positive outcome in individual.https://www.mdpi.com/2072-6694/12/5/1181bladder cancerimmunotherapycheckpoint inhibitor |
| spellingShingle | Mikołaj Wołącewicz Rafał Hrynkiewicz Ewelina Grywalska Tomasz Suchojad Tomasz Leksowski Jacek Roliński Paulina Niedźwiedzka-Rystwej Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives Cancers bladder cancer immunotherapy checkpoint inhibitor |
| title | Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives |
| title_full | Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives |
| title_fullStr | Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives |
| title_full_unstemmed | Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives |
| title_short | Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives |
| title_sort | immunotherapy in bladder cancer current methods and future perspectives |
| topic | bladder cancer immunotherapy checkpoint inhibitor |
| url | https://www.mdpi.com/2072-6694/12/5/1181 |
| work_keys_str_mv | AT mikołajwołacewicz immunotherapyinbladdercancercurrentmethodsandfutureperspectives AT rafałhrynkiewicz immunotherapyinbladdercancercurrentmethodsandfutureperspectives AT ewelinagrywalska immunotherapyinbladdercancercurrentmethodsandfutureperspectives AT tomaszsuchojad immunotherapyinbladdercancercurrentmethodsandfutureperspectives AT tomaszleksowski immunotherapyinbladdercancercurrentmethodsandfutureperspectives AT jacekrolinski immunotherapyinbladdercancercurrentmethodsandfutureperspectives AT paulinaniedzwiedzkarystwej immunotherapyinbladdercancercurrentmethodsandfutureperspectives |